Teva Furnishes Q2 2026 Financial Results and Raises Outlook
Summary
Teva Pharmaceutical Industries Ltd. announced its Q2 2026 financial results on July 29, 2026, for the quarter ended June 30, 2026, via Ex. 99.1 press release. The company reported Q2 2026 revenues of $4.1 billion, a 1% decrease year-over-year in U.S. dollars. Despite this, Teva highlighted strong growth in its key innovative brands, which collectively grew 43% year-over-year in local currency to over $1 billion. * AUSTEDO® global revenues: $696 million (+40% YoY LC). * AJOVY® global revenues: $244 million (+56% YoY LC). * UZEDY® revenues: $77 million (+43% YoY LC). * Raised 2026 revenue outlook for key innovative brands to ~$3.7 billion.
Why It Matters
Teva's strong performance in its key innovative brands, which collectively grew 43% YoY in local currency and led to a raised 2026 revenue outlook of ~$3.7 billion for these brands, signals successful execution of its "Pivot to Growth" strategy and potential for future revenue expansion.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how TEVA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View TEVA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Key Quote
“On July 29, 2026, Teva Pharmaceutical Industries Ltd. (the "Company) issued a press release announcing its financial results for the quarter ended June 30, 2026.”
— From Item 2.02
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000818686
- Filing Date
- Wednesday, July 29, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive